Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06260059
PHASE4

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

Sponsor: Anita Saraf

View on ClinicalTrials.gov

Summary

The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).

Official title: Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2i) in Adult Patients With Congenital Heart Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-09-17

Completion Date

2027-06-01

Last Updated

2025-10-06

Healthy Volunteers

No

Interventions

DRUG

Empagliflozin 10 MG

Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year

DRUG

Placebo

To patients randomized to the placebo group, a placebo pill will be given

Locations (3)

Magee Women's Hospital

Pittsburgh, Pennsylvania, United States

Presbyterian Hospital

Pittsburgh, Pennsylvania, United States

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States